13D/13G Filings - Sofinnova Crossover I SLP

Real time Form 13D and 13G transaction reports:

  • Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
  • Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
  • Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
Time period
Reported
DateTime
Transaction
Date
TypeCompany
Symbol
Filed By
Symbol
Shares Owned
% Owned
Shares Vs. Prev ReportView
2025-02-14
4:20 pm
Purchase
2024-12-3113GInventiva S.A.
IVA
Sofinnova Crossover I SLP7,792,307
7.200%
1,681,480increase
(+27.52%)
Filing
History
2025-02-14
4:19 pm
Purchase
2025-02-1413DABIVAX SA
ABVX
Sofinnova Crossover I SLP7,794,478
11.000%
845,865increase
(+12.17%)
Filing
History
2024-02-09
4:49 pm
Purchase
2023-12-3113GInventiva S.A.
IVA
Sofinnova Crossover I SLP6,110,827
9.700%
2,728,888increase
(+80.69%)
Filing
History
2023-10-30
1:42 pm
Purchase
2023-10-2013DABIVAX SA
ABVX
Sofinnova Crossover I SLP6,948,613
8.000%
6,948,613increase
(New Position)
Filing
History
2023-02-13
2:08 pm
Sale
2022-12-3113GMaxCyte, Inc.
MXCT
Sofinnova Crossover I SLP4,610,693
4.500%
-500,000decrease
(-9.78%)
Filing
History
2023-02-13
2:07 pm
Purchase
2022-12-3113GInventiva S.A.
IVA
Sofinnova Crossover I SLP3,381,939
8.000%
129,032increase
(+3.97%)
Filing
History
2022-02-11
12:00 pm
Purchase
2021-12-3113GInventiva S.A.
IVA
Sofinnova Crossover I SLP3,252,907
6.200%
138,880increase
(+4.46%)
Filing
History
2022-02-11
10:59 am
Purchase
2021-12-3113GMaxCyte, Inc.
MXCT
Sofinnova Crossover I SLP5,110,693
5.100%
5,110,693increase
(New Position)
Filing
History
2021-02-08
7:30 pm
Purchase
2020-12-3113GInventiva S.A.
IVA
Sofinnova Crossover I SLP3,114,027
10.400%
3,114,027increase
(New Position)
Filing
History